Zhang et al. [94] discovered that in three-dimensional culture, epithelial growth factor receptor tyrosine kinase inhibitor erlotinib inhibited the motility of inflammatory breast cancer (IBC) cell line SUM149 and its invasion in matrigel, accompanied with increased expression of E-cadherin and reduced expression of vimentin and β-catenin. This evidence concerns the gene CDH1 and inflammatory breast carcinoma.